Eurand Announces Data On Switching Cystic Fibrosis Patients With Exocrine Pancreatic Insufficiency From Unapproved PEPs To FDA-Approved ZENPEP(R)

Eurand Pharmaceuticals, Inc., a subsidiary of global specialty pharmaceutical company Eurand N.V. (NASDAQ: EURX), announced additional data from a post-hoc analysis of a Phase III clinical trial with ZENPEP® (pancrelipase) Delayed-Release Capsules, an FDA-approved pancreatic enzyme product (PEP) for the treatment of exocrine pancreatic insufficiency (EPI) in patients with cystic fibrosis (CF) or other conditions. The study results demonstrate that patients with EPI due to CF can be transitioned effectively from their previous PEPs to FDA-approved ZENPEP...

Short URL: http://drugrehab.in/?p=1180